In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 629 ( 2022-01-26)
Abstract:
Although monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged as an essential component of coronavirus disease 2019 (COVID-19) treatment, these therapeutics are highly specific to SARS-CoV-2. Thus, they may not be as effective against other sarbecoviruses or against variants of SARS-CoV-2. Here, Martinez et al . identified a mAb, DH1047, which binds to the receptor-binding domain (RBD) of multiple sarbecoviruses. DH1047 neutralized SARS-CoV, SARS-CoV-2, and multiple bat coronaviruses in vitro and protected mice against infection with sarbecoviruses in vivo. Together, these findings support further development of broadly cross-reactive sarbecovirus-targeting antibodies.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abj7125
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022